Author response: Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity
Simei Go(University of Oxford), Eric O’Neill(Institute of Cancer Research), Mark R. Middleton(University of Oxford), Constantinos Demetriou(University of Oxford), Edward Arbe-Barnes(University of Oxford), Keaton Jones(University of Oxford), Simone Lanfredini(University of Oxford), Shivan Sivakumar(University of Oxford), Giampiero Valenzano(Wellcome/MRC Cambridge Stem Cell Institute), Somnath Mukherjee(Post Graduate Institute of Medical Education and Research), Sophie Hughes(University of Oxford), Jennifer P. Morton(Cancer Research UK), Helen Ferry(University of Oxford), Rachael Bashford-Rogers(University of Cambridge)
Cited by 1
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
|European Journal of Cancer|2019|589
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
|European Journal of Cancer|2016|579